ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Guideline
- Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers.Neurology · 2026Article
- Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cross-sectional associations of loneliness with plasma p-tau217 and neurofilament light chain in dementia-free older adults in the INSPIRE-T baseline cohort.Journal of Alzheimer's disease : JAD · 2026Article
- Diagnostic performance of plasma pTau217 in genetically admixed South American populations.Nature communications · 2026Article
- Optimized plasma p-tau217 and p-tau217/Aβ42 cutoffs enhance detection of pre-clinical Alzheimer's disease across diverse participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy.JAMA network open · 2026Article
- Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer's disease.Aging clinical and experimental research · 2026Article
- Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system.The journal of prevention of Alzheimer's disease · 2026Article
- Optimizing cutoffs for clinical interpretation of brain amyloid status using PET/MRI: a multisite study.Alzheimer's research & therapy · 2026Article
- Plasma p-tau217, p-tau181, and Aβ42 predict amyloid PET positivity in cognitively unimpaired adults.Alzheimer's research & therapy · 2026Article
- Age-adjusted neurofilament light chain cutoffs for diagnosing neurodegenerative dementia: a two-threshold machine learning approach.GeroScience · 2026Article
- Performance of plasma pTau217, pTau181 and their ratios to Aβ42 in detecting Aβ pathology using a China-developed direct chemiluminescence assay.Alzheimer's research & therapy · 2026Article
- Diagnostic performance of plasma p-tau217 levels measured with different assays for Alzheimer's disease.Translational psychiatry · 2026Article
- Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease.NPJ Parkinson's disease · 2026Article
- Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.Brain : a journal of neurology · 2026Article
- Evaluation of plasma p-tau217 biomarkers in detecting amyloid pathology and predicting cognitive outcomes: Observations from Japanese Alzheimer's disease neuroimaging initiative cohort.The journal of prevention of Alzheimer's disease · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionWe aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p-tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice.
methodsClinical performance of plasma p-tau217 against amyloid positron emission tomography status was evaluated in participants with mild cognitive impairment or mild dementia (n = 427).
resultsUsing a one-cutpoint approach (negative/positive), neither assay achieved ≥ 90% in both sensitivity and specificity. A two-cutpoint approach yielding 92% sensitivity and 96% specificity provided the desired balance of false positives and false negatives, while categorizing 20% and 39% of results as indeterminate for the Lumipulse and ALZpath assays, respectively. DISCUSSION: This study provides a systematic framework for selection of assay-specific cutpoints for clinical use of plasma p-tau217 for determination of amyloid status. Our findings suggest that a two-cutpoint approach may have advantages in optimizing diagnostic accuracy while minimizing potential harm from false positive results. HIGHLIGHTS: Phosphorylated tau (p-tau)217 cutpoints for detection of amyloid pathology were established. A two-cutpoint approach exhibited the best performance for clinical laboratory use. p-tau217 assays differed in the percentage of results categorized as intermediate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.